Advertisement: Kao Data Centre mid banner
Advertisement: Cambridge Network mid banner
Advertisement: Mogrify mid banner
Advertisement mid banner S-Tech 1
Advertisement: RSM mid banner
Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative
Mid banner advertisement: BDO
Advertisement: EBCam mid banner
Advertisement: partnersand mid banner
Advertisement: CJBS mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: HCR Hewitsons mid banner
ARM Innovation Hub
6 October, 2021 - 14:41 By Tony Quested

New ‘Modis’ operandi as ex-GSK star boosts Mogrify’s top team

Mogrify’s new CSO has hailed game-changing technology that could help revolutionise cell therapy and in vivo reprogramming therapy and trigger a new era of hope for global sufferers across multiple disease platforms.

Dr Louise Modis is ex-GlaxoSmithKline and says she is mightily impressed with  Mogrify’s portfolio as it pioneers development of a new class of in vivo reprogramming therapies and transforms the development of ex vivo cell therapies.

The appointment follows the recent completion of a $33 million Series A funding round.

Dr Modis  is an accomplished scientific leader in therapeutic discovery and development and holds considerable experience in the progression of pre-clinical and clinical-stage assets, across various modalities and therapeutic areas. 

She will lead the advancement of Mogrify’s internal programs to help address high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.

Dr Modis has more than 20 years’ experience in pre-clinical and clinical therapeutic research. Formerly VP of Immunology Research at GSK, she led the generation and advancement of a pipeline of assets from target identification through to clinical proof-of-concept studies. 

Her roles at GSK included sponsorship of the Immunology Network, hosting external collaborators at GSK on sabbatical to nucleate and develop novel therapeutic concepts, championing in-licensing of assets, and representing GSK on the board of Sitryx. 

Prior to GSK, she led research teams at Boehringer Ingelheim Pharmaceuticals and Millennium Pharmaceuticals (now Takeda), where she progressed therapeutic candidates targeted at immunology, oncology, and cardiovascular indications with unmet need. 

Mogrify CEO Dr Darrin Disley, said: “We are delighted to welcome Louise to the Mogrify executive team following a global search that considered drug discovery specialists from across Europe and the United States. 

“Louise’s domain expertise, intellectual curiosity and passion for developing novel modalities capable of transforming clinical outcomes for patients suffering with degenerative diseases, make her an ideal fit to lead our internal programs through to first-in-human studies.”

Dr Modis added: “I am very excited to join Mogrify and to be able to deploy its powerful cell reprogramming platform to address the most immediate challenges of developing cost-effective ex vivo cell therapies in immuno-oncology. 

“I am particularly enthused by the company’s development of novel in vivo therapeutic modalities and the opportunity to progress a number of in vivo reprogramming therapies rapidly through development into the clinic.

“Mogrify has developed a set of proprietary technologies that leverage transcriptomic and epigenetic sequencing to predict the factors required for direct cellular reprogramming.

“These platforms, for the first time, make it possible to both systematically enhance the efficiency of stem cell-derived reprogramming, and directly convert (trans differentiate) mature cell types into other mature cell types (or states) without going through a pluripotent stem cell- or progenitor cell-state.

“Mogrify’s proprietary and award-winning platforms allow the company to circumvent many of the challenges associated with the development of ex vivo cell therapies, and moreover, uniquely positions Mogrify to pioneer the development of novel in vivo therapeutic modalities (conversion of cell type/state directly in the human body) for indications of high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.”

Newsletter Subscription

Stay informed of the latest news and features